Research progress of cyclin-dependent kinase 4/6 inhibitors for hormone receptor positive,human epidermal growth factor receptor 2 negative advanced breast cancer
Hormone receptor positive(HR+),+kg human epidermal growth factor receptor 2 negative(HER2-)breast cancer is the most common molecular subtype of breast cancer,with a highly variable prognosis that depends on sensitivity to endocrine agents.Resistance to endocrine therapy in HR+,HER2-advanced breast cancer patients may result in shortened survival time,deteriorated life quality,and other adverse outcomes.Therefore,it is of great significance to develop new therapy strategies.Currently an oral targeted therapy drug,cyclin-dependent kinase(CDK)4/6 inhibitor,has obtained clinical approval and changed treatment pattern of HR+,HER2-advanced breast cancer,with great improvement on survival benefits and safety,so that breast cancer guidelines recommend CDK4/6 inhibitor as one of the preferred therapy drugs for HR+,HER2-advanced patients.This review introduces research progress on mechanism,effectiveness,safety and pharmacoeconomics of CDK4/6 inhibitors.
万方数据
维普
